ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
Globe Newswire (Thu, 18-Apr 4:05 PM ET)
ANI Pharmaceuticals Financial Report: Key Insights Revealed
TipRanks (Wed, 17-Apr 8:12 AM ET)
PRNewswire (Thu, 11-Apr 11:12 AM ET)
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
Globe Newswire (Tue, 9-Apr 6:50 AM ET)
ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis
Globe Newswire (Thu, 4-Apr 6:50 AM ET)
ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium
Globe Newswire (Wed, 3-Apr 6:50 AM ET)
ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP
Globe Newswire (Wed, 27-Mar 6:50 AM ET)
Globe Newswire (Thu, 29-Feb 6:50 AM ET)
ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
Globe Newswire (Tue, 20-Feb 6:50 AM ET)
Globe Newswire (Wed, 7-Feb 6:50 AM ET)
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Ani Pharmaceuticals trades on the NASDAQ stock market under the symbol ANIP.
As of April 19, 2024, ANIP stock price climbed to $65.18 with 57,806 million shares trading.
ANIP has a beta of 0.75, meaning it tends to be less sensitive to market movements. ANIP has a correlation of 0.05 to the broad based SPY ETF.
ANIP has a market cap of $1.33 billion. This is considered a Small Cap stock.
Last quarter Ani Pharmaceuticals reported $132 million in Revenue and $1.00 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.15.
In the last 3 years, ANIP stock traded as high as $70.81 and as low as $22.31.
The top ETF exchange traded funds that ANIP belongs to (by Net Assets): IJR, VTI, IWM, VXF, PJP.
ANIP has outperformed the market in the last year with a return of +71.6%, while the SPY ETF gained +21.4%. In the last 3 month period, ANIP beat the market returning +17.3%, while SPY returned +4.4%. However, in the most recent 2 weeks ANIP has underperformed the stock market by returning -4.1%, while SPY returned -3.3%.
ANIP support price is $63.70 and resistance is $65.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANIP stock will trade within this expected range on the day.